JP2024019727A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024019727A5 JP2024019727A5 JP2023223638A JP2023223638A JP2024019727A5 JP 2024019727 A5 JP2024019727 A5 JP 2024019727A5 JP 2023223638 A JP2023223638 A JP 2023223638A JP 2023223638 A JP2023223638 A JP 2023223638A JP 2024019727 A5 JP2024019727 A5 JP 2024019727A5
- Authority
- JP
- Japan
- Prior art keywords
- sgrna
- nme
- nucleotides
- length
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584310P | 2017-11-10 | 2017-11-10 | |
| US62/584,310 | 2017-11-10 | ||
| US201762596375P | 2017-12-08 | 2017-12-08 | |
| US62/596,375 | 2017-12-08 | ||
| US201862667084P | 2018-05-04 | 2018-05-04 | |
| US62/667,084 | 2018-05-04 | ||
| PCT/US2018/060126 WO2019094791A2 (en) | 2017-11-10 | 2018-11-09 | Targeted crispr delivery platforms |
| JP2020525971A JP2021502097A (ja) | 2017-11-10 | 2018-11-09 | 標的化ｃｒｉｓｐｒ送達プラットフォーム |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525971A Division JP2021502097A (ja) | 2017-11-10 | 2018-11-09 | 標的化ｃｒｉｓｐｒ送達プラットフォーム |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024019727A JP2024019727A (ja) | 2024-02-09 |
| JP2024019727A5 true JP2024019727A5 (enExample) | 2025-04-17 |
Family
ID=66438139
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525971A Withdrawn JP2021502097A (ja) | 2017-11-10 | 2018-11-09 | 標的化ｃｒｉｓｐｒ送達プラットフォーム |
| JP2023223638A Pending JP2024019727A (ja) | 2017-11-10 | 2023-12-28 | 標的化ｃｒｉｓｐｒ送達プラットフォーム |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525971A Withdrawn JP2021502097A (ja) | 2017-11-10 | 2018-11-09 | 標的化ｃｒｉｓｐｒ送達プラットフォーム |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20220389447A9 (enExample) |
| EP (1) | EP3707254A4 (enExample) |
| JP (2) | JP2021502097A (enExample) |
| KR (2) | KR102922730B1 (enExample) |
| CN (1) | CN111868240A (enExample) |
| AU (2) | AU2018364993B2 (enExample) |
| BR (1) | BR112020009268A2 (enExample) |
| CA (1) | CA3082370A1 (enExample) |
| CO (1) | CO2020007046A2 (enExample) |
| IL (2) | IL317505A (enExample) |
| MX (1) | MX2020004777A (enExample) |
| SG (1) | SG11202005103RA (enExample) |
| WO (1) | WO2019094791A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7250031B2 (ja) * | 2018-09-25 | 2023-03-31 | 公益財団法人微生物化学研究会 | 新規ウイルスベクターおよびその製造方法と使用方法 |
| CN113661392B (zh) | 2019-02-05 | 2025-05-27 | 卡蒂亚生物公司 | 有效靶向基因组操纵剂的增强选择 |
| CN113728097A (zh) * | 2019-02-14 | 2021-11-30 | 宏基因组学知识产权技术有限责任公司 | 具有ruvc结构域的酶 |
| CN110257406B (zh) * | 2019-06-21 | 2022-07-22 | 安徽省农业科学院水稻研究所 | 密码子植物化改造的Plant Nme2Cas9基因及其应用 |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| WO2021122944A1 (en) | 2019-12-18 | 2021-06-24 | Alia Therapeutics Srl | Compositions and methods for treating retinitis pigmentosa |
| CN113652411B (zh) * | 2021-07-30 | 2025-01-10 | 复旦大学 | Cas9蛋白、含有Cas9蛋白的基因编辑系统及应用 |
| CN119452085A (zh) | 2021-08-27 | 2025-02-14 | 宏基因组学公司 | 具有ruvc结构域的酶 |
| US20230183687A1 (en) * | 2021-10-13 | 2023-06-15 | University Of Massachusetts | Modified guide rnas for neisseria meningitidis cas9 |
| EP4426836A1 (en) * | 2021-11-03 | 2024-09-11 | Intellia Therapeutics, Inc. | Modified guide rnas for gene editing |
| EP4426822A2 (en) | 2021-11-03 | 2024-09-11 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for genome editing |
| CN119998446A (zh) | 2022-06-07 | 2025-05-13 | 斯克里贝治疗公司 | 用于靶向pcsk9的组合物和方法 |
| JP2026506287A (ja) | 2022-12-21 | 2026-02-24 | インテリア セラピューティクス，インコーポレイテッド | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）編集のための組成物及び方法 |
| WO2024186890A1 (en) | 2023-03-06 | 2024-09-12 | Intellia Therapeutics, Inc. | Compositions and methods for hepatitis b virus (hbv) genome editing |
| WO2025038646A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Cd70 car-t compositions and methods for cell-based therapy |
| TW202515994A (zh) | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對ｃｄ７０進行基因修飾之組合物及方法 |
| WO2025038648A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025255308A1 (en) | 2024-06-07 | 2025-12-11 | Intellia Therapeutics, Inc. | Cd8 co-receptor chimeric polypeptides in tcr cell therapy |
| WO2026163162A1 (en) | 2025-01-31 | 2026-08-06 | Intellia Therapeutics, Inc. | Enhanced cas9 variants and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2728782T3 (es) * | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| JP6738728B2 (ja) | 2013-06-17 | 2020-08-19 | ザ・ブロード・インスティテュート・インコーポレイテッド | 肝臓ターゲティングおよび治療のためのＣＲＩＳＰＲ−Ｃａｓ系、ベクターおよび組成物の送達および使用 |
| CN105517579B (zh) * | 2013-07-10 | 2019-11-15 | 哈佛大学校长及研究员协会 | 用于RNA向导的基因调节和编辑的正交Cas9蛋白 |
| EP3760719A1 (en) * | 2013-11-18 | 2021-01-06 | CRISPR Therapeutics AG | Crispr-cas system materials and methods |
| US10450586B2 (en) * | 2013-11-28 | 2019-10-22 | Horizon Discovery Limited | Somatic haploid human cell line |
| JP6793547B2 (ja) * | 2013-12-12 | 2020-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物 |
| WO2015089473A1 (en) * | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
| WO2016049258A2 (en) * | 2014-09-25 | 2016-03-31 | The Broad Institute Inc. | Functional screening with optimized functional crispr-cas systems |
| US10190106B2 (en) * | 2014-12-22 | 2019-01-29 | Univesity Of Massachusetts | Cas9-DNA targeting unit chimeras |
| US20160346359A1 (en) * | 2015-05-01 | 2016-12-01 | Spark Therapeutics, Inc. | Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease |
| US11732258B2 (en) * | 2016-11-02 | 2023-08-22 | President And Fellows Of Harvard College | Engineered guide RNA sequences for in situ detection and sequencing |
| SG11201912024RA (en) * | 2017-07-31 | 2020-02-27 | Sigma Aldrich Co Llc | Synthetic guide rna for crispr/cas activator systems |
-
2018
- 2018-11-09 BR BR112020009268-1A patent/BR112020009268A2/pt unknown
- 2018-11-09 IL IL317505A patent/IL317505A/en unknown
- 2018-11-09 AU AU2018364993A patent/AU2018364993B2/en active Active
- 2018-11-09 KR KR1020207016690A patent/KR102922730B1/ko active Active
- 2018-11-09 EP EP18876344.5A patent/EP3707254A4/en active Pending
- 2018-11-09 SG SG11202005103RA patent/SG11202005103RA/en unknown
- 2018-11-09 CN CN201880082218.2A patent/CN111868240A/zh active Pending
- 2018-11-09 CA CA3082370A patent/CA3082370A1/en active Pending
- 2018-11-09 WO PCT/US2018/060126 patent/WO2019094791A2/en not_active Ceased
- 2018-11-09 MX MX2020004777A patent/MX2020004777A/es unknown
- 2018-11-09 JP JP2020525971A patent/JP2021502097A/ja not_active Withdrawn
- 2018-11-09 IL IL274526A patent/IL274526B2/en unknown
- 2018-11-09 KR KR1020267003248A patent/KR20260023096A/ko active Pending
- 2018-11-09 US US16/186,352 patent/US20220389447A9/en not_active Abandoned
-
2020
- 2020-06-10 CO CONC2020/0007046A patent/CO2020007046A2/es unknown
-
2023
- 2023-01-06 AU AU2023200084A patent/AU2023200084B2/en active Active
- 2023-12-28 JP JP2023223638A patent/JP2024019727A/ja active Pending
-
2024
- 2024-03-21 US US18/612,111 patent/US20250223611A1/en active Pending
- 2024-12-13 US US18/980,456 patent/US20250197889A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Parambi et al. | Gene therapy approach with an emphasis on growth factors: theoretical and clinical outcomes in neurodegenerative diseases | |
| AU2019258678B2 (en) | Lipid-based formulations for the delivery of RNA | |
| Rettig et al. | Progress toward in vivo use of siRNAs-II | |
| US20210277371A1 (en) | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation | |
| JP5735573B2 (ja) | ポリヌクレオチドのインビボ送達のためのポリ結合体 | |
| TWI924663B (zh) | 用於抑制ＰＮＰＬＡ３表現之ＲＮＡｉ劑、其醫藥組成物及使用方法 | |
| BR112017012482B1 (pt) | Composição, usos de uma composição, e, métodos para liberar um ácido nucleico a uma célula ou tecido alvo e para a produção da composição | |
| JP2024511808A (ja) | ウイルスベクターに基づくｒｎａ送達システム及びその使用 | |
| Leclerc et al. | Next-generation biological vector platforms for in vivo delivery of genome editing agents | |
| JP2022523806A (ja) | 閉端ｄｎａ（ｃｅｄｎａ）および免疫調節化合物 | |
| CN115869332A (zh) | 递送至体内后在肝脏少表达的mRNA药物及其制备方法 | |
| WO2023124740A1 (zh) | 肌肉高亲和性的新型腺相关病毒衣壳蛋白及其应用 | |
| CN120019152A (zh) | 用于表达蛋白质的人工多核苷酸 | |
| WO2024236361A1 (en) | Compositions and methods for delivery of nucleic acids to cells | |
| Mathew et al. | Heat-shrinking DNA nanoparticles for in vivo gene delivery | |
| KR102685034B1 (ko) | 금속 나노 입자-핵산 결합체를 기반으로 하는 유전자 운반체 | |
| CN121752723A (zh) | 编码crispr相关蛋白的核酸及其应用 | |
| CN117618381A (zh) | 肝脏肿瘤靶向药物及其制备方法和应用 | |
| CN119998457A (zh) | 基于金属纳米颗粒-核酸缀合物的基因载体 | |
| EP3836903B1 (en) | Lipid-based formulations containing salts for the delivery of rna | |
| Chand et al. | Advances in Gene Therapy for Neurologic Disorders: An Overview | |
| Singh et al. | The Junction of Biomaterials and Gene Therapy–Current Strategies and Future Directions | |
| CN118634243B (zh) | Mir2911在制备抗登革病毒denv的药物中的应用 | |
| US20250376664A1 (en) | Virus-Ribonucleoprotein Conjugates | |
| Bogadi et al. | Nucleic acid-based micellar therapy for the treatment of different diseases |